Adolescent Overdose Prevention and SUD Treatment Initiative (R34 - Clinical Trial Optional)

Active
No
Status
Posted
Published Date
November 17th, 2023
Close Date
March 13th, 2024
Opportunity No.
RFA-DA-25-031

Agency

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Summary

The National Institutes of Health is offering a grant opportunity titled "Adolescent Overdose Prevention and SUD Treatment Initiative (R34 - Clinical Trial Optional)". This grant aims to support pilot work and preliminary research to prepare for large-scale trials that will guide the expansion of effective overdose prevention, substance use disorder (SUD) treatment, and recovery services for adolescents. The studies funded by this grant may include examining changes in risk behaviors associated with overdose, such as using drugs alone or carrying/using Naloxone. The desired outcomes include harm reduction, recovery, treatment retention and effectiveness, quality of care, patient-centered outcomes, and implementation factors. The goal is to develop interventions that are effective, practical, cost-effective, scalable, and sustainable in addressing overdose prevention, SUD treatment, and recovery services for youth. Other eligible applicants include Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), eligible agencies of the Federal Government, faith-based or community-based organizations, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Indian/Native American Tribal Governments (Other than Federally Recognized), non-domestic (non-U.S.) entities (Foreign Organizations), regional organizations, Tribally Controlled Colleges and Universities (TCCUs), and U.S. Territories or Possessions. The grant does not require cost sharing or matching. The deadline for applications is March 13, 2024. For more information and to apply, visit the following link: Adolescent Overdose Prevention and SUD Treatment Initiative Grant. For any inquiries, contact NIH Grants Information at grantsinfo@nih.gov.

Description

This Notice of Funding Opportunity (NOFO) encourages pilot work and preliminary research to support preparation for large-scale, rigorous trials that will guide the expansion of effective, non-stigmatizing overdose prevention, SUD treatment and recovery services for adolescents. These studies could include examining changes in risk behaviors associated with overdose (e.g., using alone, carrying/using Naloxone). Outcomes of interest include but are not limited to harm reduction, recovery, treatment retention and effectiveness, quality of care, patient-centered outcomes, and implementation factors. The goal of this NOFO is to develop interventions that address effective, non-stigmatizing overdose prevention, SUD treatment and recovery services for youth that are effective, practical, cost-effective, scalable, and sustainable.

Contact Information

Attachments
0 KB

Opportunity Lifecycle

Title
Type
Grant

Similar Opportunities

HEAL Initiative: Translating Research to Practice to End the Overdose Crisis (R61/R33 Clinical Trial Optional)
National Institutes of Health
The National Institutes of Health (NIH) is offering a grant opportunity titled "HEAL Initiative: Translating Research to Practice to End the Overdose Crisis (R61/R33 Clinical Trial Optional)". This grant falls under the category of Income Security and Social Services. The purpose of this grant is to support translational dissemination and implementation research focused on addressing overdose deaths and the intersection of pain and Opioid Use Disorder (OUD). The grant is expected to run for two years (FY23 and FY24) and has a maximum award ceiling of $750,000. Eligible applicants include various institutions and organizations, such as Alaska Native and Native Hawaiian Serving Institutions, Faith-based or Community-based Organizations, and Historically Black Colleges and Universities (HBCUs). Non-domestic (non-U.S.) entities and components are not eligible to apply. The deadline for applications is March 20, 2025. For more information and to apply, please visit the following link: [http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-23-053.html](http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-23-053.html).
Development of Medications to Prevent and Treat Opioid and/or Stimulant Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)
National Institutes of Health
The National Institutes of Health is offering a federal grant opportunity titled "Development of Medications to Prevent and Treat Opioid and/or Stimulant Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)". This grant aims to support the discovery and development of medications to prevent and treat opioid and/or psychostimulant use disorders and overdose. The funding instrument type for this opportunity is a Cooperative Agreement. The grant falls under the category of funding activity related to health. The grant does not require cost sharing or matching. The eligible applicants for this grant include various institutions and organizations such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), Eligible Agencies of the Federal Government, Faith-based or Community-based Organizations, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Indian/Native American Tribal Governments (Other than Federally Recognized), Non-domestic (non-U.S.) Entities (Foreign Organizations), Regional Organizations, Tribally Controlled Colleges and Universities (TCCUs), and U.S. Territory or Possession. The purpose of this grant is to support the discovery and development of medications that can prevent and treat opioid and/or psychostimulant use disorders and overdose. The grant involves two phases, UG3 and UH3. The UG3 phase provides support for a project with specific milestones to be accomplished within a 2-year period. The UH3 phase provides funding for 3 years to a project that successfully completes the milestones set in the UG3 phase. Projects that meet their milestones in the UG3 phase will be considered for transition to the UH3 phase. The grant encourages applications that include preclinical or clinical research studies with high impact and quick results to advance medications closer to FDA approval for the prevention and treatment of opioid use disorders and overdose. The compounds to be evaluated can be small molecules or biologics, and they can be tested in pre-clinical models or for the clinical manifestations of opioid use disorders such as withdrawal, craving, relapse, or overdose. The grant also supports the development of new chemical entities, new formulations of marketed medications available for other indications, or combinations of medications that hold promise for the treatment of opioid use disorders and overdose. The goal of this grant is to fast-track the discovery and development of medications to prevent and treat opioid use disorders or opioid overdose and advance them in the FDA's drug development approval pipeline. For more information and to apply for this grant opportunity, please visit the following link: [Development of Medications to Prevent and Treat Opioid and/or Stimulant Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)](http://grants.nih.gov/grants/guide/pa-files/PAR-22-200.html). If you have any inquiries, you can contact NIH Grants Information at grantsinfo@nih.gov.
Behavioral and Integrative Treatment Development Program (R34 Clinical Trial Optional)
National Institutes of Health
The National Institutes of Health is offering a grant opportunity titled "Behavioral and Integrative Treatment Development Program (R34 Clinical Trial Optional)". This grant aims to support research on behavioral intervention development, including testing efficacy, conducting clinical trials, examining behavior change mechanisms, and optimizing treatment strategies. The grant focuses on various drug abuse treatment interventions, adherence interventions, interventions to prevent HIV transmission, and interventions for substance misuse and chronic pain. The grant is open to various eligible applicants, including federal agencies, academic institutions, and community-based organizations. The deadline for application submission is March 21, 2025. For more information and to apply, visit the following link: [http://grants.nih.gov/grants/guide/pa-files/PAR-22-183.html](http://grants.nih.gov/grants/guide/pa-files/PAR-22-183.html).
Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional)
National Institutes of Health
The National Institutes of Health is offering a grant opportunity titled "Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional)". This grant aims to support clinical research projects that focus on understanding the neurobiological mechanisms underlying Substance Use Disorders (SUD) and fundamental brain function relevant to substance use. The grant utilizes a R61/R33 Phased Innovation Award mechanism and is particularly designed to support exploratory and developmental projects that require budgets exceeding those allowed for the R21 mechanism. The grant does not require cost sharing or matching. The eligible applicants include various institutions and organizations such as Alaska Native and Native Hawaiian Serving Institutions, Faith-based or Community-based Organizations, and U.S. Territories or Possessions. The closing date for this grant opportunity is May 7, 2026. For more information and to apply, please visit the following link: [Exploratory Clinical Neuroscience Research on Substance Use Disorders Grant](http://grants.nih.gov/grants/guide/pa-files/PAR-23-157.html). For any inquiries, please contact NIH Grants Information at grantsinfo@nih.gov.